Researcher Profile

Darin Vanderpool

🏛 Mirati Therapeutics, Inc., San Diego, California. 1

0009-0008-9941-0240

Publications

787

Citations

Co-Authors

Active Years

Publications

Open Access Journal Article Molecular Cancer Therapeutics Apr 19, 2024

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar · Larry Yan · Fadia Qiryaqos · Lars D. Engstrom +30 more

10.1158/1535-7163.mct-23-0870 24 citations

Journal Article Cancer Research Jun 15, 2022

Abstract ND02: MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers

John M. Ketcham · Shilpi Khare · Niranjan Sudhakar · David M. Briere +21 more

10.1158/1538-7445.am2022-nd02 4 citations

Open Access Journal Article Journal of Medicinal Chemistry Jul 14, 2022

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

John M. Ketcham · Jacob Haling · Shilpi Khare · Vickie Bowcut +22 more

10.1021/acs.jmedchem.2c00741 88 citations

Open Access Journal Article Journal of Medicinal Chemistry Dec 10, 2021

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

Xiaolun Wang · Shelley Allen · James F. Blake · Vickie Bowcut +24 more

10.1021/acs.jmedchem.1c01688 671 citations

Publication Timeline

2024

2022

2021

Frequent Co-Authors

4×

4×

4×

4×

4×

4×

4×

4×

3×

3×